Limitation Of Fnac

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, considering the individual patient's circumstances and current evidence-based guidelines. The field of medicine is constantly evolving, and information may become outdated. Always exercise professional clinical judgment.

Overview

• Definition: Fine Needle Aspiration Cytology (FNAC) is a minimally invasive diagnostic procedure used to obtain cellular material from a suspicious lesion (e.g., a palpable lump or an image-detected abnormality) for cytological examination. The "limitations" of FNAC refer to the inherent constraints, potential inaccuracies, and circumstances under which it may not provide a definitive or fully representative diagnosis, necessitating further investigation.
• Epidemiology: The diagnostic accuracy and limitations of FNAC vary significantly depending on the site of aspiration (e.g., thyroid, breast, lymph node, salivary gland), the prevalence of specific pathologies in a given population, the experience of the operator and cytopathologist, and the availability of ancillary techniques. While FNAC generally boasts high sensitivity and specificity for many conditions, non-diagnostic rates typically range from 5-20%, and false negative rates from 1-10% in various studies, particularly for smaller or challenging lesions. False positive rates are generally low (often <1%).
• Classification: Limitations can be broadly classified based on their origin:
  • Sampling limitations: Inadequate cellularity, non-representative sampling, sampling of necrotic/cystic areas, geographic miss.
  • Interpretive limitations: Cytomorphologic overlap between benign and malignant entities, presence of reactive changes mimicking neoplasia, lack of architectural context, limited ancillary studies.
  • Lesion-specific limitations: Certain pathologies (e.g., follicular thyroid lesions, well-differentiated liposarcoma, lymphoma subtypes) may inherently be difficult to diagnose definitively by cytology alone due to the need for architectural assessment or specific immunophenotyping.
  • Operator-dependent limitations: Lack of experience in performing the aspiration or preparing the smears.
  • Pathologist-dependent limitations: Lack of experience in cytological interpretation.

Pathophysiology

This section is reframed to describe the underlying reasons for FNAC limitations rather than the pathophysiology of a disease. - Mechanism: The fundamental mechanism leading to FNAC limitations revolves around the inherent nature of cytology (examining individual cells or small cell clusters) compared to histology (examining tissue architecture). * Sampling Error: Cells are aspirated from a lesion, but this sample may not be representative of the entire lesion, especially if it's heterogeneous, cystic, fibrotic, or focally malignant. A "geographic miss" can occur if the needle does not enter the target area. * Insufficient Material: Aspiration may yield too few cells (hypocellularity), making diagnosis impossible or inconclusive. * Cellular Degeneration/Obscurity: Blood, necrosis, or cyst fluid can obscure cellular details, making interpretation difficult. * Loss of Architecture: Cytology primarily assesses cellular morphology and arrangement, but critical diagnostic features for many lesions (e.g., invasion, growth pattern, capsular integrity in follicular neoplasms) are based on tissue architecture, which is largely absent in FNAC samples. * Cytomorphologic Overlap: Benign and malignant conditions can sometimes share similar cellular features (e.g., reactive lymph nodes vs. lymphoma, benign follicular adenoma vs. follicular carcinoma). * Limited Ancillary Studies: While immunohistochemistry (IHC) and molecular testing can be performed on cell blocks or liquid-based cytology, the quantity and quality of material may be insufficient for a full panel, especially compared to core biopsy tissue. - Risk Factors: Factors increasing the likelihood of FNAC limitations: * Lesion Characteristics: * Small size: Difficult to target accurately. * Deep location: Requires imaging guidance, potentially increasing risk of sampling error. * Cystic or necrotic lesions: Often yield acellular fluid or degenerated cells. * Fibrotic or sclerotic lesions: Yield sparse cellular material. * Heterogeneous lesions: A single aspirate may miss the diagnostic area. * Vascular lesions: Prone to blood contamination, obscuring cells. * Procedural Factors: * Inexperienced operator: Suboptimal needle placement, inadequate aspiration technique, poor smear preparation. * Lack of imaging guidance: For non-palpable or deep lesions, leading to sampling error. * Absence of Rapid On-Site Evaluation (ROSE): ROSE allows immediate assessment of smear adequacy, reducing non-diagnostic rates. * Suboptimal smear preparation: Thick smears, air-drying artifacts, crushing artifacts. * Pathology Factors: * Inexperienced cytopathologist: Misinterpretation or over/under-calling. * Inherent limitations of cytology for specific entities: Lymphoma subtyping, follicular thyroid neoplasms, some mesenchymal tumors. - Protective Factors: Factors that mitigate or reduce FNAC limitations: * Experienced operator: Skilled in accurate targeting, adequate sampling, and optimal smear preparation. * Image guidance (ultrasound, CT): For non-palpable or deep lesions, ensuring accurate needle placement. * Rapid On-Site Evaluation (ROSE): Immediate assessment of smear adequacy, ensuring sufficient diagnostic material and allowing for immediate re-aspiration if needed. It also allows for triage of samples for ancillary studies. * Adequate smear preparation: Thin, evenly spread smears, proper fixation. * Experienced cytopathologist: Proficient in interpreting various cytological presentations and recognizing pitfalls. * Availability of ancillary studies: Cell block preparation for IHC, molecular testing. * Multidisciplinary Team (MDT) discussion: Correlation of clinical, radiological, and cytological findings to arrive at a comprehensive diagnosis.

Clinical Presentation

This section is reframed to describe how FNAC limitations manifest in the diagnostic process rather than patient symptoms.

Signs and Symptoms

• Cardinal Features:
  • Non-diagnostic (ND) or Inadequate Sample: The most common "limitation," where the material obtained is insufficient for diagnosis (e.g., acellular, hypocellular, obscured by blood). Leads to a need for repeat biopsy or alternative diagnostic procedures.
  • Indeterminate/Equivocal Result: The sample shows atypical features but is not clearly benign or malignant (e.g., Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) in thyroid, Atypical Squamous Cells of Undetermined Significance (ASC-US) in cervical cytology, Atypical Glandular Cells (AGC)). This indicates diagnostic uncertainty.
  • Discordance with Clinical/Radiological Findings: The FNAC result does not align with the clinical suspicion or imaging features (e.g., FNAC benign but imaging highly suspicious for malignancy; FNAC malignant but lesion appears benign).
  • False Negative (FN) Result: Malignancy is present but not detected by FNAC. This delays definitive diagnosis and treatment.
  • False Positive (FP) Result: A benign lesion is misdiagnosed as malignant by FNAC. This can lead to unnecessary anxiety and potentially unnecessary invasive procedures.
• Early Signs:
  • High cellularity but with obscured details (e.g., by blood or inflammation) during rapid on-site evaluation (if performed).
  • Scant cellularity noted during immediate slide preparation.
  • Cytopathologist noting significant atypia but without sufficient features for definitive malignancy, leading to a "suspicious" or "indeterminate" category.
• Advanced Signs:
  • Persistent or growing lesion despite a prior benign FNAC result, raising suspicion of a false negative.
  • Need for multiple repeat FNACs due to persistent non-diagnostic results.
  • Surgical excision revealing a different diagnosis than indicated by FNAC (e.g., malignancy after benign FNAC, or benign lesion after suspicious FNAC).
• Atypical Presentations:
  • FNAC provides a specific diagnosis (e.g., specific tumor type) but subsequent excisional biopsy reveals a different, albeit related, pathology or a higher grade.
  • Diagnosis of a primary tumor by FNAC, but subsequent workup reveals it's a metastasis from an unknown primary.

Physical Examination

This section is reframed to discuss physical findings that might indicate inherent challenges or limitations for FNAC. - Inspection: * Skin changes: Inflammation, ulceration over a lesion might indicate an inflammatory or infectious process rather than a neoplastic one, or complicate FNAC. * Multiple lesions: Suggests a systemic process (e.g., lymphoma, metastatic disease) where FNAC may diagnose the type but not the primary source, or where multiple sites may need sampling. - Palpation: * Deep-seated or non-palpable lesions: Require image guidance, increasing complexity and potential for sampling error if guidance is suboptimal. * Highly mobile lesions: Difficult to stabilize during aspiration, increasing risk of sampling error. * Very hard/fibrotic lesions: May yield insufficient cellular material due to resistance to needle penetration and aspiration. * Cystic or fluctuant lesions: Often yield fluid with sparse cells or degenerated material. * Diffuse or ill-defined lesions: Challenging to target a specific representative area for sampling. - Special Tests: Not directly applicable to physical examination related to FNAC limitations, but the findings from imaging (e.g., ultrasound, CT, MRI characteristics) are crucial for assessing the lesion's suitability for FNAC and predicting potential limitations.

Diagnostic Approach

This section focuses on identifying and addressing FNAC limitations.

History Taking

• Key Questions:
  • Previous biopsies/FNACs: Were they performed? What were the results (e.g., non-diagnostic, indeterminate, benign, malignant)? Were they discordant with clinical findings?
  • Duration and evolution of the lesion: Rapid growth or recent changes may suggest malignancy, making a benign FNAC result more concerning (potential false negative).
  • Symptoms: Presence of pain, fever, weight loss, night sweats, or other systemic symptoms that might suggest inflammation, infection, or malignancy (aids in clinical-cytological correlation).
  • Risk factors: History of cancer, radiation exposure, family history relevant to the lesion site.
  • Anticoagulant use: Increases risk of hematoma, which can obscure the sample.
• Red Flags: Warning signs that an FNAC result might be limited or misleading:
  • Persistent growth or clinical suspicion of malignancy despite benign FNAC.
  • High suspicion on imaging (e.g., highly suspicious BIRADS 4/5 for breast, TIRADS 4/5 for thyroid) with benign or indeterminate FNAC.
  • Non-diagnostic FNAC in a patient with strong clinical suspicion for malignancy.
  • Discordance between FNAC result and other diagnostic modalities.

Laboratory Tests

This section typically refers to blood tests. For FNAC limitations, laboratory tests are usually not directly indicative of the limitation itself, but rather used to correlate with FNAC findings or guide further workup. - First-Line: Not applicable for assessing FNAC limitations directly. However, in certain contexts (e.g., thyroid nodules), thyroid function tests (TSH, free T4) are performed prior to FNAC. - Confirmatory: No specific lab tests directly confirm FNAC limitations. Rather, subsequent histopathological examination (e.g., core needle biopsy, excisional biopsy) serves as the "gold standard" to confirm or refute FNAC findings and therefore reveal its limitations in a specific case. - Monitoring: Not applicable for FNAC limitations. Monitoring refers to patient follow-up. If an FNAC is non-diagnostic or indeterminate, further monitoring or re-evaluation is necessary.

Imaging

• Recommended: Imaging is often performed before FNAC to characterize the lesion and during FNAC (e.g., ultrasound, CT) to guide the aspiration. Imaging also plays a crucial role in evaluating FNAC limitations:
  • Ultrasound (US): Highly recommended for palpable and superficial lesions (breast, thyroid, lymph nodes) to guide needle placement, ensure accurate sampling, and assess lesion characteristics (e.g., cystic vs. solid, vascularity, suspicious features). A US-guided FNAC has a lower non-diagnostic rate than palpation-guided FNAC for non-palpable lesions.
  • Computed Tomography (CT): Used for deep-seated lesions (e.g., lung, retroperitoneum, mediastinum) where ultrasound is not feasible. CT guidance helps in precise needle placement.
  • Magnetic Resonance Imaging (MRI): Less commonly used for real-time guidance but can provide detailed characterization of lesions, helping to interpret FNAC results (e.g., identifying areas of necrosis or hemorrhage within a lesion that might explain a non-diagnostic FNAC).
• Advanced:
  • PET-CT: May be used in oncology settings to characterize metabolically active lesions. A benign FNAC of a highly PET-avid lesion would raise suspicion of a false negative.
  • Elastography: Used in conjunction with ultrasound for breast and thyroid lesions to assess stiffness, which can correlate with malignancy. A soft lesion with a malignant FNAC would be an unusual discordance.

Management

This section focuses on managing the clinical situation when FNAC yields a limited or inconclusive result.

Acute Management

• Immediate: If FNAC yields a non-diagnostic or equivocal result in the setting of high clinical suspicion, the immediate management involves discussing the findings with the patient and planning further investigation.
• Stabilization: Not applicable in the context of FNAC limitations for a disease, but rather for ensuring diagnostic clarity. The priority is to obtain a definitive diagnosis without undue delay.
• Emergency: While FNAC limitations are not medical emergencies themselves, a false negative in an aggressive malignancy could lead to delayed treatment, which could constitute an "oncologic emergency" by virtue of progression.

Chronic Management

This section is reframed to describe subsequent diagnostic steps and ongoing management strategies for addressing FNAC limitations. - Pharmacological: Not applicable for managing FNAC limitations. - Non-pharmacological: * Repeat FNAC: Often the first step for a non-diagnostic or unsatisfactory sample, especially if the lesion is easily accessible and the initial sample was technically limited. Image guidance (e.g., ultrasound) and Rapid On-Site Evaluation (ROSE) should be employed if not used previously. * Core Needle Biopsy (CNB): The preferred next step when FNAC is non-diagnostic, indeterminate, or discordant with clinical/radiological findings, particularly for lesions where architectural assessment is crucial (e.g., breast, prostate, lung, follicular thyroid lesions, suspected lymphoma). CNB provides tissue cores for histology and more extensive ancillary studies. * Excisional Biopsy/Surgical Excision: May be indicated if CNB is also non-diagnostic or if there's high suspicion for malignancy despite benign or indeterminate biopsy results, or for lesions where CNB is technically challenging or carries higher risk. For some indeterminate thyroid nodules, diagnostic lobectomy may be performed. * Observation with Serial Imaging: For lesions with low clinical suspicion, small size, and a benign or non-diagnostic FNAC, especially if repeat biopsy is risky or patient preference, close follow-up with serial imaging may be an option. However, this carries the risk of delayed diagnosis. * Multidisciplinary Team (MDT) Discussion: Essential for complex or discordant cases, bringing together surgeons, radiologists, oncologists, pathologists, and other specialists to review all available information and determine the optimal diagnostic and therapeutic plan. - Monitoring: * Clinical and radiological follow-up: For cases managed with observation, regular follow-up appointments and imaging (e.g., ultrasound, CT) are crucial to detect any changes or progression that would necessitate further intervention.

Treatment Algorithms

This section outlines pathways for managing results with FNAC limitations. - First-Line: * Non-diagnostic FNAC: * With ROSE: If ROSE confirmed inadequacy, repeat FNAC with more passes or different technique, or proceed directly to CNB if suspicion is high. * Without ROSE: Repeat FNAC, preferably with ROSE or image guidance. If repeat is also non-diagnostic, proceed to CNB or excisional biopsy. * Indeterminate/Equivocal FNAC: * Low suspicion (clinical/radiological): Consider repeat FNAC or observation. * Moderate/High suspicion: Proceed to CNB or molecular testing (e.g., for thyroid nodules). * Discordant FNAC (e.g., benign FNAC on suspicious imaging): Always pursue further tissue diagnosis (CNB or excisional biopsy) as FNAC is less definitive than histology. - Second-Line: * If repeat FNAC or CNB is still non-diagnostic or indeterminate, and clinical suspicion remains high, surgical excision for definitive diagnosis is often recommended. * For specific contexts (e.g., thyroid nodules), molecular testing on FNAC or CNB material may help risk stratify indeterminate results and guide management (e.g., avoiding unnecessary surgery). - Refractory Cases: * When multiple attempts at minimally invasive biopsy fail to provide a diagnosis in a suspicious lesion, surgical biopsy (incisional or excisional) becomes necessary. * For highly suspicious but technically challenging lesions, therapeutic intervention (e.g., empirical chemotherapy for suspected lymphoma or surgery for suspected cancer) might be considered in very rare, extreme circumstances only after extensive MDT discussion and ruling out all other options, weighing risks and benefits carefully.

Complications

This section addresses complications arising from the limitations of FNAC itself, rather than from the procedure. - Common: * Delayed diagnosis: The most significant complication of a false negative or non-diagnostic FNAC, leading to disease progression and potentially worse outcomes. * Patient anxiety: Uncertainty from indeterminate or non-diagnostic results can cause significant psychological distress. * Need for repeat procedures: Multiple biopsies increase patient discomfort, cost, and potential for procedural complications (e.g., bleeding, infection). - Serious: * Unnecessary invasive procedures: A false positive can lead to unwarranted surgery or aggressive treatment. * Suboptimal treatment: If FNAC provides an inaccurate subtyping (e.g., lymphoma subtyping), leading to incorrect chemotherapy regimen. * Increased morbidity/mortality: Direct consequence of delayed diagnosis of a malignancy, allowing it to progress to a more advanced, less treatable stage. - Long-term: * Compromised prognosis: For malignancies, delayed diagnosis due to FNAC limitations can lead to a less favorable prognosis. * Cumulative scarring/tissue damage: From multiple biopsy attempts.

Prognosis

This section focuses on the impact of FNAC limitations on the patient's overall prognosis for the underlying condition. - Factors: The impact of FNAC limitations on prognosis is directly related to: * Nature of the underlying disease: Aggressive malignancies are more impacted by diagnostic delays than indolent ones. * Timeliness of corrective action: How quickly a non-diagnostic or discordant FNAC is followed up by definitive diagnostic procedures. * Lesion characteristics: Smaller, easily accessible lesions are less prone to persistent limitations than large, deep, or complex ones. * Clinical judgment: The ability of the clinician to recognize potential FNAC limitations and pursue further investigation appropriately. - Survival: While FNAC limitations themselves do not directly cause mortality, they can indirectly affect survival by delaying the diagnosis and treatment of malignant conditions. High non-diagnostic rates or false negatives in screening programs (e.g., thyroid cancer, lung cancer) can translate into later-stage diagnoses and potentially reduced survival rates for the cohort. - Quality of Life: Indeterminate or non-diagnostic results lead to prolonged diagnostic workup, multiple procedures, and significant patient anxiety, thereby negatively impacting quality of life during the diagnostic phase.

Prevention

This section focuses on strategies to minimize or prevent the occurrence and impact of FNAC limitations.

• Primary: Strategies to prevent the occurrence of FNAC limitations:
  • Operator Training and Expertise: Comprehensive training in aspiration technique, smear preparation, and proper handling of samples.
  • Image Guidance: Routinely using ultrasound or CT guidance for non-palpable or deep lesions to ensure accurate targeting.
  • Rapid On-Site Evaluation (ROSE): Implementing ROSE whenever feasible to assess sample adequacy and triage material for ancillary studies, significantly reducing non-diagnostic rates.
  • Adequate Needle Gauge and Technique: Using appropriate needle sizes (e.g., 22-27 gauge) and proper aspiration/non-aspiration techniques suitable for the lesion.
  • Optimal Smear Preparation: Producing thin, even, and well-fixed smears to minimize obscuring elements and preserve cellular morphology.
• Secondary: Early detection and intervention to address limitations once they are identified (e.g., an equivocal result):
  • Interdisciplinary Collaboration: Establishing close communication between clinicians, radiologists, and cytopathologists. Regular multidisciplinary team (MDT) meetings for complex cases.
  • Correlation of Findings: Always correlating FNAC results with clinical history, physical examination, and imaging findings.
  • Ancillary Studies: Preparing cell blocks routinely to allow for immunohistochemistry (IHC) and molecular studies when needed, enhancing diagnostic accuracy and overcoming some cytomorphological overlaps.
  • Use of Standardized Reporting Systems: Adopting standardized terminology (e.g., Bethesda System for Thyroid Cytopathology, Milan System for Salivary Gland Cytopathology) to ensure clear communication of diagnostic categories and recommended follow-up.
• Tertiary: Preventing complications arising from limitations (e.g., delayed diagnosis):
  • Prompt Follow-up for Indeterminate/Non-diagnostic Results: Developing clear algorithms for managing FNAC results that are not definitively benign or malignant, leading to timely repeat biopsies or definitive excisional biopsies.
  • Patient Education: Informing patients about the potential for non-diagnostic or indeterminate results and the need for further procedures.

Special Populations

• Pediatric:
  • FNAC in children often requires sedation or general anesthesia, increasing procedural complexity and risk.
  • Certain pediatric tumors (e.g., lymphomas, sarcomas) are often challenging to diagnose definitively by FNAC alone, requiring core biopsy or excisional biopsy for architectural assessment and ancillary studies.
  • The psychological impact of repeated procedures and diagnostic uncertainty can be greater in children and their families.
• Geriatric:
  • Comorbidities and anticoagulant use are more common, increasing the risk of procedural complications (e.g., bleeding).
  • Older patients may have more fibrotic lesions, leading to lower cellularity.
  • Tolerance for multiple procedures may be lower. Careful consideration of the risk-benefit ratio for further invasive procedures is important.
• Pregnancy:
  • FNAC is generally considered safe during pregnancy. However, caution is advised regarding imaging guidance involving radiation (e.g., CT). Ultrasound guidance is preferred.
  • Interpretation can be challenging in some sites (e.g., breast lesions during pregnancy/lactation often show prominent physiological changes that can mimic atypia).
  • Diagnostic delays or definitive treatment decisions may be postponed until after delivery if the lesion is not aggressive.
• Comorbidities:
  • Coagulopathy: Increases risk of bleeding and hematoma formation, which can obscure the aspirate. Requires careful assessment of clotting status and potential correction.
  • Immunocompromised patients: May have atypical presentations of infections or malignancies, making cytological interpretation more complex and increasing risk of false negatives.
  • Prior radiation/surgery: May alter tissue texture (fibrosis), making aspiration more difficult and potentially yielding hypocellular samples.

Clinical Pearls

• Diagnostic:
  • "Triple Test": For breast lesions, combine clinical examination, imaging (mammogram/ultrasound), and FNAC/biopsy. Discordance in any component mandates further investigation (e.g., excisional biopsy), even if FNAC is benign. This concept applies broadly to other sites where multiple diagnostic modalities are used.
  • Always correlate: Never interpret an FNAC result in isolation. Always integrate it with clinical history, physical findings, and imaging characteristics.
  • ROSE is key: When available, insist on Rapid On-Site Evaluation (ROSE) as it dramatically reduces non-diagnostic rates and ensures proper sample triaging for ancillary studies.
  • Cell block for ancillary studies: For adequate material, preparing a cell block from the FNAC washings or clot can be invaluable for performing immunohistochemistry (IHC) or molecular studies, which are often critical for definitive diagnosis, especially for lymphomas, soft tissue tumors, or metastatic disease.
• Treatment:
  • Don't treat an FNAC: Definitive treatment (especially surgical excision for malignancy) should ideally be based on histopathological confirmation (core needle biopsy or excisional biopsy), not solely on FNAC, unless the FNAC is unequivocally malignant in a setting where surgical management is standard.
  • Follow guidelines: Adhere to site-specific guidelines (e.g., Bethesda system for thyroid nodules, National Comprehensive Cancer Network (NCCN) guidelines) for managing indeterminate or non-diagnostic FNAC results.
• Pitfalls:
  • Over-reliance on benign FNAC: A benign FNAC result in a clinically or radiologically suspicious lesion should never be accepted as definitive. It is often a false negative due to sampling error.
  • Misinterpretation of reactive changes: Reactive lymphoid hyperplasia, reparative processes, or inflammatory changes can sometimes mimic malignancy on cytology, leading to false positives.
  • Insufficient material for subtyping: Even if malignancy is diagnosed, FNAC may not provide enough material or architectural context for precise subtyping, which is crucial for treatment planning (e.g., in lymphomas or sarcomas).
  • Cystic lesions: Often yield fluid with few diagnostic cells, leading to non-diagnostic results. A benign fluid aspirate from a suspicious cyst should be followed by evaluation of the cyst wall or repeat imaging.

Recent Updates

• Guidelines:
  • Increased emphasis on molecular testing: Especially in thyroid nodule management (e.g., Afirma, ThyroSeq) to risk-stratify indeterminate (AUS/FLUS, Follicular Neoplasm/Suspicious for Follicular Neoplasm - FN/SFN) FNAC results, potentially avoiding unnecessary surgeries.
  • Refinement of standardized reporting systems: Ongoing updates to systems like Bethesda (Thyroid), Milan (Salivary Gland), and the WHO Classification of Tumours, providing clearer diagnostic categories and management recommendations, thus reducing interpretive ambiguity.
  • Recommendations for repeat biopsy: Current guidelines increasingly recommend core needle biopsy over repeat FNAC for persistent non-diagnostic or highly suspicious FNAC results, particularly when architectural assessment is paramount.
• Evidence:
  • Recent studies continue to support the value of Rapid On-Site Evaluation (ROSE) in significantly improving FNAC diagnostic yield and reducing non-diagnostic rates across various sites.
  • Growing evidence highlights the utility of immunohistochemistry (IHC) and molecular profiling on cell blocks from FNAC samples for precise tumor classification and guiding targeted therapies, mitigating the limitation of lack of tissue architecture.
  • Research into artificial intelligence (AI) for automated FNAC smear analysis shows promise in aiding cytopathologists, potentially improving diagnostic consistency and reducing inter-observer variability.
• Controversies:
  • The precise role of molecular testing vs. repeat biopsy/surgery for indeterminate results: Balancing cost-effectiveness, turnaround time, and diagnostic yield remains a debate, particularly in regions with limited resources.
  • Utility of FNAC for certain sites/lesions: Debate continues regarding the optimal role of FNAC vs. core biopsy as a primary diagnostic tool for specific lesions (e.g., some soft tissue tumors, certain lymphomas) where architectural context is critical for classification.
  • Standardization of non-diagnostic criteria: While general criteria exist, slight variations in "adequacy" definitions can still contribute to inter-institutional differences in non-diagnostic rates.

Key References

• Guidelines:
  • Haugen, B. R., et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1-133. (Refer to section on FNAC interpretation and management of indeterminate results).
  • Cibas, E. S., & Ducatman, B. S. (2014). Cytology: Diagnostic Principles and Clinical Correlates. Elsevier Saunders. (Standardized reporting systems like Bethesda).
  • NCCN Clinical Practice Guidelines in Oncology (various sites): Provides comprehensive, evidence-based management guidelines for various cancers, including diagnostic pathways where FNAC plays a role, and subsequent steps when FNAC is inconclusive.
• Studies:
  • Mazzaferri, E. L., & Kloos, R. T. (2007). Clinical review: Current approaches to the diagnosis and treatment of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 92(10), 3824-3844. (Discusses FNAC role and limitations in thyroid).
  • Layfield, L. J., et al. (2018). Rapid On-Site Evaluation (ROSE) of Fine-Needle Aspiration Biopsy Specimens: A Review of 2018 Literature and an Assessment of Practice. Diagnostic Cytopathology, 46(12), 1017-1025.
  • Valderrabano, R., et al. (2020). Performance of Thyroid Molecular Testing for Indeterminate Cytology: A Systematic Review and Meta-analysis. Thyroid, 30(2), 200-211.
• Reviews:
  • Rosenthal, D. L., et al. (2012). Fine-Needle Aspiration Cytology: A Guide to the Contemporary Practice of Cytology. American Journal of Clinical Pathology, 137(3), 481-490.
  • O'Regan, K., & Munk, P. L. (2015). Imaging-Guided Fine-Needle Aspiration Biopsy. In Clinical Procedures in Medical Practice (pp. 53-70). Springer, Cham. (Focuses on technical aspects and imaging guidance to mitigate limitations).